ARHGAP39

Across TCGA pan-cancer cohorts, ARHGAP39 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGAP39 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGAP39 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP39 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where ARHGAP39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.496	0.870	.038	6	view →
LUAD	DFS	Quartile	All	0.424	1.000	.008	6	view →
LSCC	DFS	Tertile	II,III,IV	0.858	1.000	.009	5	view →
OV	DFS	Median	All	0.852	1.000	.034	4	view →
UCEC	DFS	Median	II,III,IV	0.855	0.505	.039	4	view →
GBM	OS	Tertile	All	0.293	0.617	.039	2	view →
PDAC	OS	Median	III,IV	0.876	0.461	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARHGAP39–HNSC (OS)

Open the HNSC breakdown →